Bicocca Open Archive

Logo unimib boa
LUPPI, FABRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.551
AS - Asia 9.604
EU - Europa 6.304
SA - Sud America 1.752
AF - Africa 189
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 6
Totale 30.425
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.224
SG - Singapore 3.107
VN - Vietnam 1.922
HK - Hong Kong 1.824
CN - Cina 1.772
RU - Federazione Russa 1.464
IT - Italia 1.460
BR - Brasile 1.425
IE - Irlanda 918
DE - Germania 735
SE - Svezia 569
GB - Regno Unito 328
ID - Indonesia 218
UA - Ucraina 203
CA - Canada 189
AR - Argentina 146
IN - India 142
FR - Francia 138
KR - Corea 108
FI - Finlandia 98
MX - Messico 92
ZA - Sudafrica 91
BD - Bangladesh 87
JP - Giappone 83
NL - Olanda 79
AT - Austria 77
TR - Turchia 73
PL - Polonia 55
EC - Ecuador 54
PK - Pakistan 45
IQ - Iraq 40
ES - Italia 36
MA - Marocco 29
BE - Belgio 28
CO - Colombia 28
DK - Danimarca 28
PY - Paraguay 28
SA - Arabia Saudita 25
UZ - Uzbekistan 23
CL - Cile 21
PE - Perù 21
CH - Svizzera 18
EG - Egitto 17
TW - Taiwan 17
AU - Australia 15
CZ - Repubblica Ceca 15
AE - Emirati Arabi Uniti 14
TN - Tunisia 13
KE - Kenya 12
UY - Uruguay 11
DZ - Algeria 10
LT - Lituania 10
MY - Malesia 10
PH - Filippine 10
VE - Venezuela 10
HN - Honduras 8
DO - Repubblica Dominicana 7
IL - Israele 7
IR - Iran 7
MN - Mongolia 7
RO - Romania 7
AZ - Azerbaigian 6
BG - Bulgaria 6
JM - Giamaica 6
JO - Giordania 6
KZ - Kazakistan 6
BB - Barbados 5
PT - Portogallo 5
BH - Bahrain 4
BO - Bolivia 4
CR - Costa Rica 4
GE - Georgia 4
KG - Kirghizistan 4
LB - Libano 4
LV - Lettonia 4
NP - Nepal 4
NZ - Nuova Zelanda 4
OM - Oman 4
PS - Palestinian Territory 4
RS - Serbia 4
TT - Trinidad e Tobago 4
AM - Armenia 3
BY - Bielorussia 3
ET - Etiopia 3
EU - Europa 3
HU - Ungheria 3
MU - Mauritius 3
NG - Nigeria 3
SV - El Salvador 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
BN - Brunei Darussalam 2
CI - Costa d'Avorio 2
GT - Guatemala 2
GY - Guiana 2
LK - Sri Lanka 2
MM - Myanmar 2
MT - Malta 2
NI - Nicaragua 2
PA - Panama 2
Totale 30.397
Salva come PNG Salva come JPEG
Città #
Singapore 1.904
Hong Kong 1.822
Ann Arbor 1.515
Fairfield 1.223
Ashburn 1.110
Dublin 900
Ho Chi Minh City 611
Wilmington 605
Woodbridge 518
Seattle 509
Hanoi 478
Chandler 474
Frankfurt am Main 473
Houston 458
New York 412
Dallas 405
Cambridge 390
Princeton 370
Milan 369
Santa Clara 355
Beijing 273
Hefei 273
Dearborn 272
Los Angeles 213
Jakarta 180
Moscow 166
Altamura 160
Nanjing 156
Jacksonville 150
Lawrence 139
São Paulo 133
Chicago 114
Seoul 104
Buffalo 100
Shanghai 98
Rome 95
Munich 87
The Dalles 82
Ottawa 80
San Diego 77
London 70
Haiphong 69
Andover 65
Da Nang 60
Nuremberg 59
Guangzhou 54
Tokyo 48
Boardman 47
Johannesburg 47
Dong Ket 46
Warsaw 44
Rio de Janeiro 43
Vienna 43
Shenyang 42
Hebei 41
Helsinki 41
Toronto 40
Ha Long 39
Council Bluffs 37
Can Tho 36
Fremont 35
Mexico City 35
Nanchang 35
Biên Hòa 34
Salt Lake City 34
Brasília 33
Lappeenranta 33
Monza 33
Hải Dương 32
Quận Bình Thạnh 32
Stockholm 32
Atlanta 31
Jinan 29
Denver 28
Montreal 28
Ninh Bình 27
Phoenix 27
Brooklyn 26
Poplar 25
Porto Alegre 25
Thái Nguyên 25
Changsha 24
Elk Grove Village 24
Jiaxing 24
Bắc Ninh 23
Columbus 23
Kent 23
Tianjin 23
Turku 23
Brussels 22
Norwalk 22
Tashkent 22
Bologna 21
Chennai 21
Tampa 21
Amsterdam 19
Ankara 19
Belo Horizonte 19
Bắc Giang 19
Quận Một 19
Totale 19.874
Salva come PNG Salva come JPEG
Nome #
Percent Predicted vs. Absolute Six-Minute Walk Distance as Predictors of Lung Transplant-Free Survival in Fibrosing Interstitial Lung Diseases 469
The ‘Liaisons dangereuses’ Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation 412
Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers 358
Diagnostic delay in bronchiectasis: an Italian perspective 355
Early referral to palliative care services in patients with IPF: A tool to take a step forward 354
What remains of long COVID after four years from hospitalization for severe COVID pneumonia 321
Healthcare costs and resources utilization in children with difficult-to-control asthma treated with biologic therapies: A population-based cohort study 308
Use of 6-minute walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases 299
Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study 293
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 288
Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential 276
Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study 267
One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study 264
Janus-faced amiodarone-induced pneumopathy 254
Non-tuberculous mycobacteria pulmonary disease: an integrated approach beyond antibiotics 251
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 250
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? 249
Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study 243
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 240
Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis 236
Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study 232
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 231
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 226
Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study 211
A multidisciplinary approach to screen the post-COVID-19 conditions 210
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 209
Cigarette smoke extract (CSE) induces clusterion expression in human lung fibroblasts. 209
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases 209
Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis 206
Six-Month Pulmonary Impairment after Severe COVID-19: A Prospective, Multicentre Follow-Up Study 203
Cigarette smoke upregulates clusterin expression and apoptosis in human bronchial epithelial cells 202
Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study 197
Molecular biomarkers in idiopathic pulmonary fibrosis: State of the art and future directions 195
Short-term Evolution of Nutritional Status in Patients with Idiopathic Pulmonary Fibrosis 194
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust 193
Characteristics of long COVID after two years of follow-up in a previously hospitalized population 186
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 186
Clinical differences in sarcoidosis patients with and without lymphoma: A single-centre retrospective cohort analysis 185
Clinical Characteristics of Anti-synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project 184
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 184
What patients with Idiopathic Pulmonary Fibrosis and caregivers want - Filling the currents gaps with patient reported outcomes and experience measures 183
Feasibility of CPAP application and variables related to worsening of respiratory failure in pregnant women with SARS-CoV-2 pneumonia: Experience of a tertiary care centre 183
Therapeutic Management of Bronchiectasis in Children and Adolescents: A Concise Narrative Review 181
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis 177
Healthcare costs and resource utilisation in bronchiectasis, asthma and COPD 175
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19 175
Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic 174
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 174
Nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis and right heart dysfunction: A prespecified subgroup analysis of a double-blind randomized clinical trial (instage) 172
The impact of COVID-19 infection on idiopathic pulmonary fibrosis mortality: a systematic review and meta-analysis 171
Progression and prognosis of interstitial pneumonia with autoimmune features: a longitudinal, prospective, multi-centre study 170
Feasibility and clinical impact of a portable bi-level ventilation device in patients with severe chronic obstructive pulmonary disease and exertional dyspnea: preliminary results from a clinical series 170
Impact of N-acetyl-L-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study 165
Cardiovascular Structural and Functional Parameters in Idiopathic Pulmonary Fibrosis at Disease Diagnosis 164
Diagnosis of asthma and copd 163
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 159
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial 157
Frailty and long-COVID: is COVID-19 responsible for a transition in frailty status among older adults who survived hospitalization for COVID-19? 156
Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach 156
Best supportive care for idiopathic pulmonary fibrosis: Current gaps and future directions 153
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 153
Acute exacerbation of idiopathic pulmonary fibrosis: Lessons learned from acute respiratory distress syndrome? 150
Multidisciplinary approach to systemic diseases: benefits for diagnosis and management of complex disorders 150
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review 148
Interstiziopatia polmonare non classificabile o secondaria a connettivite indifferenziata. importanza e difficoltà di una diagnosi differenziale 148
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment 147
Evaluation of preoperative cardiopulmonary reserve and surgical risk of patients undergoing lung cancer resection 144
Management of fixed airflow limitation caused by asthma or chronic obstructive pulmonary disease 144
High serum levels of silica nanoparticles in systemic sclerosis patients with occupational exposure: Possible pathogenetic role in disease phenotypes 143
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 143
Questionnaires May Help Pulmonologists for Referral of Patients With IPF to a Holistic Approach 141
Interstitial pneumonitis with autoimmune features (IPAF): A work in progress 141
Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis 141
Digital health technologies for improving the management of people with chronic obstructive pulmonary disease 140
Idiopathic interstitial pneumonia in a patient with von Hippel-Lindau syndrome: a first case 140
Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: A multicenter prospective study 140
Rheumatoid arthritis extra-articular lung disease: new insights on pathogenesis and experimental drugs 139
Sleep-Disordered Breathing and Chronic Respiratory Infections: A Narrative Review in Adult and Pediatric Population 139
Management of Idiopathic Pulmonary Fibrosis 139
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 139
Interstitial pneumonia associated with autoimmune diseases: a possible mimicker of SARS-CoV-2 pneumonia 139
The Multiple Components of COPD 137
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 136
Effects of cigarette smoke condensate on proliferation and wound closure of bronchial epithelial cells in vitro: role of glutathione 136
Clinical performance of a commercial real-time PCR assay for Aspergillus DNA detection in serum samples from high-risk patients: comparison with a galactomannan enzyme immunoassay 135
Sarcoidosis: challenging diagnostic aspects of an old disease 135
The usual Interstitial pneumonia pattern in autoimmune rheumatic diseases 134
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: A case report 134
Update in chronic obstructive pulmonary disease 2006 131
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows 131
Update in chronic obstructive pulmonary disease 2005 130
Treatment of acute exacerbation in interstitial lung disease secondary to autoimmune rheumatic diseases: More questions than answers 129
Guiding ILD management in systemic autoimmune rheumatic diseases 129
Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases 129
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 129
Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres 128
Cystic lung in sarcoidosis: Clinico-radiologic characteristic and evolution 128
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies 128
Evaluation of serum (1 → 3)-β-d-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors 127
Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation 127
Totale 18.918
Salva come PNG Salva come JPEG
Categoria #
all - tutte 119.750
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 119.750
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.465 0 0 0 0 0 234 206 286 146 233 155 205
2021/20221.845 154 208 190 193 90 120 84 124 98 95 160 329
2022/20232.726 417 725 264 172 169 468 38 134 166 24 84 65
2023/20242.467 55 66 93 76 330 607 547 85 281 33 35 259
2024/20257.621 400 1.168 430 326 609 308 546 218 687 1.115 586 1.228
2025/20269.576 2.499 1.593 1.480 2.077 1.812 115 0 0 0 0 0 0
Totale 31.440